Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

Trial Profile

A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs HIV vaccine-vCP2438 (Primary) ; AS01B; MF 59
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms HVTN120
  • Most Recent Events

    • 19 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 27 Sep 2018 Planned number of patients changed from 320 to 160.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top